In-hospital fatality and venous thromboembolism during the first and second COVID-19 waves at a center opting for standard-dose thromboprophylaxis

Association between Early Absolute Neutrophil Count and Level of D-Dimer among Patients with COVID-19 Infection in Central Taiwan

“…The prevalence of VTE in patients with COVID may be affected not only by disease severity but also by the intensity of surveillance. Mumoli et al recently reported the incident VTE events during the first wave (February 2020 to April 2020, n = 316) and second wave (October 2020 to December 2020, n = 160) with comparable disease severity at an Italian hospital [13]. They found that the use of CTA to diagnose PE increased from 3.8% (12/316) to 8.8% (14/160), and the application of compression ultrasound to diagnose DVE also increased from 45% (143/316) to 71% (114/160) [13].…”

“…Mumoli et al recently reported the incident VTE events during the first wave (February 2020 to April 2020, n = 316) and second wave (October 2020 to December 2020, n = 160) with comparable disease severity at an Italian hospital [13]. They found that the use of CTA to diagnose PE increased from 3.8% (12/316) to 8.8% (14/160), and the application of compression ultrasound to diagnose DVE also increased from 45% (143/316) to 71% (114/160) [13]. Therefore, the increased prevalence of VTE from 13.9% (44/316) to 18.1% (29/160) might at least partly result from increased vigilance and active surveillance for VTE in patients with COVID-19.…”

“…In the present study, the need for anticoagulant was based on the aforementioned multidisciplinary discussion. In brief, we closely monitored the level and D-dimer and administered prophylactic anticoagulant with enoxaparin 40 mg/day among patients whose D-dimer was higher than 3.0 ug/mL, approximately 6× the upper limit of normal [13]. In patients with highly elevated D-dimer or signs of a thromboembolic event, the needed examinations, including computed tomography angiography (CTA) and magnetic resonance angiography (MRA), were arranged to precisely diagnose the thromboembolic event.…”

Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial

“…Similarly, we faced the surge of different variants of SARS-CoV-2 over time, which might have been characterised by different severity in terms of thrombogenicity and letality. 16 Data on SARS-CoV-2 variants were not routinely collected in the study, but epidemiological data indicates that OVID enrolment was stopped just before the surge of the omicron variants. 17 Thus far, OVID data are only available 30 days after the enrolment of the last patient; however, follow-up at 90 days has just been completed for the last patient enrolled and the results will be integrated in a subsequent report.…”

Deaths related to pulmonary embolism and cardiovascular events before and during the 2020 COVID-19 pandemic: An epidemiological analysis of data from an Italian high-risk area

“…Indeed, one cannot exclude that the increased number of in situ pulmonary thrombosis detected during the course of the pandemic could partly explain this rise [25] . However, the published information concerning the period February–March 2020 from the so-called “red areas” in Italy, including Veneto, suggests a much lower prevalence of pulmonary embolism compared to other European regions a few weeks later, but a similar overall fatality [26] , [27] , [28] . This is consistent with the challenging logistic situation caused by a novel disease [10] and with the fact that several centers, in line with available guidances, opted for a routine increase in the dosage of anticoagulation for COVID-19 patients with progressive respiratory worsening even in the absence of a confirmed pulmonary embolism diagnosis.…”